A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer

Anti-Cancer Drugs

Volumn 17, Issue 10, 2006, Pages 1201-1209

  Rocca, Andrea ^a   Peruzzotti, Giulia ^a   Ghisini, Raffaella ^a   Viale, Giuseppe ^a,b   Veronesi, Paolo ^a,b   Luini, Alberto ^a   Intra, Mattia ^a   Pietri, Elisabetta ^a   Curigliano, Giuseppe ^a   Giovanardi, Filippo ^a   Maisonneuve, Patrick ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Fluorouracil; Ki 67; Pathological complete remission; Perioperative chemotherapy; Preoperative chemotherapy

Indexed keywords

AMINOTRANSFERASE; ANTHRACYCLINE; BILIRUBIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PYRIDOXINE; SEROTONIN ANTAGONIST; TAMOXIFEN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REGIMEN; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; INFECTION; INJECTION SITE PAIN; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; VEIN THROMBOSIS; VOMITING;

ADULT; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PERIOPERATIVE CARE; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750534980     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000236306.43209.2b     Document Type: Article

References (38)

1. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000; 18:1558-1569.
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24:1940-1949.
3. Kjellgren K, Nissen-Meyer R, Norin T. Perioperative adjuvant chemotherapy in breast cancer. The Scandinavian Adjuvant Chemotherapy Study 1. Acta Oncol 1989; 28:899-901.
4. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320:491-496.
5. Sertoli MR, Bruzzi P, Pronzato P, Queirolo P, Amoroso D, Del Mastro L, et al. Randomized cooperative study of perioperative chemotherapy in breast cancer. J Clin Oncol 1995; 13:2712-2721.
6. Clahsen PC, van de Velde CJ, Goldhirsch A, Rossbach J, Sertoli MR, Bijnens L, et al. Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. J Clin Oncol 1997; 15:2526-2535.
7. Colleoni M, Curigliano G, Minchella I, Peruzzotti G, Nole F, Mazzarol G, et al. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Ann Oncol 2003; 14:1477-1483.
8. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13:424-429.
9. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999; 35:574-579.
10. American Joint Committee on Cancer. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
11. Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 5:612-618.
12. Common Toxicity Criteria (CTC) Version 2.0. April 30 1999 [http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf].
13. Miller AB, Hoogstraten B, Staquet M,Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
14. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180:297-306.
15. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10:6622-6628.
16. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 43:1488-1492.
17. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39:3861-3865.
18. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992; 176:1375-1379.
19. Ono I, Gunji H, Suda K, Iwatsuki K, Kaneko F. Evaluation of cytokines in donor site wound fluids. Scand J Plast Reconstr Surg Hand Surg 1994; 28:269-273.
20. Reid SE, Kaufman MW, Murthy S, Scanlon EF. Perioperative stimulation of residual cancer cells promotes local and distant recurrence of breast cancer. J Am Coll Surg 1997; 185:290-306.
21. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152:1445-1452.
22. Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer 1999; 79:1392-1398.
23. Hormbrey E, Han C, Roberts A, McGrouther DA, Harris AL. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res 2003; 9:4332-4339.
24. Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, et al. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat 2005; 93:35-40.
25. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003; 362:527-533.
26. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-153.
27. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16:1723-1739.
28. 1 cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 2002; 48:6-13.
29. Iwatani Y, Kamigaki T, Suzuki S, Ohno M, Nakamura T, Kuroda Y. Proliferating cell nuclear antigen as a predictor of therapeutic effect of continuous 5-fluorouracil administration in gastric cancer. Int J Oncol 1999; 14:965-970.
30. Tagawa Y, Kawazoe N, Sawai T, Yamaguchi S, Tomita M. Relationship between the Ki-67 nuclear antigen content and cell-cycle perturbation on WiDr cells treated with 5-FU. Hum Cell 1993; 6:121-125.
31. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
32. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-10874.
33. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-8423.
34. Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001; 19:4141-4149.
35. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000; 18:584-590.
36. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102:3738-3743.
37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
38. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.